StockData
Curis Inc logo

Curis Inc (CRIS) shareholders

CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/3092% below fair value
$0.54+0.11 (+24.32%)

Close on Nov 17, 2026Market cap $1.13MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
32.1%
1M of 2M shares
Institutional holders
37
7 new, 11 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $5.50K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Daniel Mack
Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%)
4,215,1659.99%13G (passive) amendmentMar 31, 2026
Wilmot B. Harkey
Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%)
4,215,1659.99%13G (passive)Mar 31, 2026
Stonepine Capital, L.P.
Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine GP, LLC (9.90%) and 1 more
4,025,9929.90%13G (passive)Mar 17, 2026
Nantahala Capital Partners Limited Partnership2,944,0006.98%13G (passive)Mar 31, 2026
Steven Boyd
Joint filing with Armistice Capital, LLC (9.99%)
1,287,3379.99%13G (passive) amendmentJun 30, 2025
Bleichroeder LP
Joint filing with Bleichroeder Holdings LLC (9.90%), Andrew Gundlach (9.90%)
1,035,6629.90%13G (passive)Mar 31, 2025
Maverick Capital Management, LLC
Joint filing with Maverick Capital, Ltd. (8.00%), Lee S. Ainslie III (8.00%)
681,3818.00%13G (passive) amendmentDec 31, 2024
Thomas A. Satterfield, Jr.616,5658.80%13G (passive) amendmentSep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CRISValueChange% of portfolio
Bleichroeder LP190,1169.10%$1.99M–0.36%
Stonepine Capital Management, LLC165,6097.92%$1.73M−20,7110.98%
Nantahala Capital Management, LLC98,9444.73%$1.03M−1,0560.02%
Cable Car Capital, LP66,6673.19%$696.13K–0.01%
CM Management, LLC27,5001.32%$287.16K+20,0000.19%
Morgan Stanley25,2151.21%$263.29K+12,5030.00%
Vanguard Capital Management LLC17,1920.82%$179.49K−1,5240.00%
Geode Capital Management, LLC14,6550.70%$153.04K+6,2390.00%
M28 Capital Management LP14,2440.68%$148.74K–0.32%
Flputnam Investment Management Co12,2880.59%$128.31KNew0.00%
Renaissance Technologies LLC7,0990.34%$74.12K−11,2380.00%
XTX Topco Ltd5,4080.26%$56.47KNew0.00%
Sphera Funds Management Ltd.4,9500.24%$1.03M−94,7970.13%
Northern Trust Corp4,7940.23%$50.05K+4,2690.00%
Vanguard Fiduciary Trust Co3,0830.15%$32.19K–0.00%
BlackRock, Inc.2,6670.13%$27.85K−70.00%
Focused Wealth Management, Inc2,5020.12%$26.13K−2,9850.00%
Maverick Capital Ltd2,4780.12%$6.19K–0.00%
Gsa Capital Partners Llp1,1380.05%$12.00KNew0.00%
State Street Corp1,0520.05%$10.99K–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026371M32.1%7 / 510 / 110M0M
Q1 2026421M37.7%11 / 126 / 91M0M
Q4 2025410M10.4%5 / 710 / 50M0M
Q3 2025410M11.0%4 / 135 / 50M0M
Q2 2025420M10.3%5 / 77 / 30M0M
Q1 2025400M11.2%5 / 610 / 40M0M
Q4 2024400M7.7%10 / 143 / 20M0M
Q3 2024320M4.8%4 / 56 / 50M0M
Q2 2024340M5.5%2 / 125 / 40M0M
Q1 2024360M5.0%5 / 95 / 70M0M
Q4 2023380M5.6%8 / 89 / 50M0M
Q3 2023350M5.1%34 / 01 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
James E. DentzerPresident & CEO, Director148,7307.12%Jul 9, 2026
Jonathan B. ZungCDO66,6673.19%Jul 9, 2026
Diantha DuvallCFO77,7073.72%Jul 9, 2026
Ahmed Hamdy MDCMO66,6673.19%Mar 23, 2026
John HohnekerDirector––Jul 9, 2026
Martyn D. GreenacreDirector26,0891.25%Jul 9, 2026
Kenneth I. KaitinDirector11,4070.55%Jul 9, 2026
Anne Elizabeth BorgmanDirector––Jul 9, 2026
Marc RubinDirector28,1081.34%Jul 9, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Kenneth I. Kaitin
Director
Mar 31, 2026Buy+10,000$0.55$5.50K11,407
Jonathan B. Zung
CDO
Mar 20, 2026Conversion+66,667––66,667
Ahmed Hamdy MD
CMO
Mar 20, 2026Conversion+66,667––66,667
James E. Dentzer
President & CEO, Director
Mar 20, 2026Conversion+133,333––148,730
Diantha Duvall
CFO
Mar 20, 2026Conversion+66,666––77,707
Marc Rubin
Director
Mar 20, 2026Conversion+26,667––28,108
James E. Dentzer
President & CEO, Director
Jan 31, 2022Sale(10b5-1 plan)−3,094$3.07$9.50K64,877
James E. Dentzer
President & CEO, Director
Jan 27, 2022Sale(10b5-1 plan)−2,406$3.18$7.65K67,971
James E. Dentzer
President & CEO, Director
Jan 26, 2021Sale(10b5-1 plan)−3,094$10.59$32.77K67,268
James E. Dentzer
President & CEO, Director
Jan 25, 2021Sale(10b5-1 plan)−2,283$10.96$25.02K70,362
James E. Dentzer
President & CEO, Director
Jan 24, 2020Sale(10b5-1 plan)−3,094$1.64$5.07K42,158
James E. Dentzer
President & CEO, Director
Jan 23, 2020Sale(10b5-1 plan)−3,658$1.69$6.18K45,252
James E. Dentzer
President & CEO, Director
Jan 24, 2019Sale(10b5-1 plan)−3,094$1.16$3.59K41,639
Kenneth I. Kaitin
Director
Jan 23, 2019Sale(10b5-1 plan)−14,800$1.05$15.54K28,121
Marc Rubin
Director
Jan 23, 2019Sale(10b5-1 plan)−18,500$1.05$19.43K28,819
James E. Dentzer
President & CEO, Director
Jan 23, 2019Sale(10b5-1 plan)−2,397$1.09$2.61K44,733
Robert Martell
Head of Research & Development
Jan 23, 2019Sale(10b5-1 plan)−5,500$1.07$5.89K23,027
Robert Martell
Head of Research & Development
Jan 23, 2019Tax withholding−8,473$1.07$9.07K28,527
Martyn D. Greenacre
Director
Jan 23, 2019Sale(10b5-1 plan)−18,500$1.05$19.43K26,089
Lori Anne Kunkel
Director
Jan 23, 2019Sale(10b5-1 plan)−14,800$1.05$15.54K22,200
Lori Anne Kunkel
Director
Jan 22, 2018Award+185,000––185,000
Kenneth I. Kaitin
Director
Jan 22, 2018Award+185,000––214,607
Marc Rubin
Director
Jan 22, 2018Award+185,000––236,596
Robert Martell
Director
Jan 22, 2018Award+185,000––185,000
James E. Dentzer
Chief Financial Officer
Jan 22, 2018Award+206,250––212,011
Martyn D. Greenacre
Director
Jan 22, 2018Award+185,000––222,945
Ali Ph.D. Fattaey
President & CEO, Director
Jan 22, 2018Award+206,250––322,140
David Tuck
Chief Medical Officer
Jan 22, 2018Award+133,750––169,424
Marc Rubin
Director
Nov 16, 2017Buy+25,000$0.98$24.50K51,596
Ali Ph.D. Fattaey
President & CEO, Director
Nov 15, 2017Buy+50,000$1.06$53.00K115,890
Kenneth I. Kaitin
Director
May 31, 2017Tax withholding−12,193$1.71$20.85K29,607
Kenneth I. Kaitin
Director
May 31, 2017Option exercise+10,000$1.39$13.90K36,800
Kenneth I. Kaitin
Director
May 31, 2017Option exercise+5,000$1.39$6.95K41,800
Martyn D. Greenacre
Director
May 31, 2017Tax withholding−12,193$1.71$20.85K37,945
Martyn D. Greenacre
Director
May 31, 2017Option exercise+5,000$1.39$6.95K50,138
Martyn D. Greenacre
Director
May 31, 2017Option exercise+10,000$1.39$13.90K45,138
James R. McNab
Director
May 5, 2017Sale(10b5-1 plan)−16,176$1.90$30.73K50,000
James R. McNab
Director
May 5, 2017Sale(10b5-1 plan)−16,176$1.90$30.73K50,000
James R. McNab
Director
May 4, 2017Sale(10b5-1 plan)−30,100$1.97$59.30K66,176
James R. McNab
Director
May 4, 2017Sale(10b5-1 plan)−30,100$1.97$59.30K66,176
James R. McNab
Director
May 3, 2017Sale(10b5-1 plan)−30,000$2.18$65.40K96,276
James R. McNab
Director
May 3, 2017Sale(10b5-1 plan)−30,000$2.18$65.40K96,276
James R. McNab
Director
May 2, 2017Sale(10b5-1 plan)−35,646$2.31$82.34K126,276
James R. McNab
Director
May 1, 2017Sale(10b5-1 plan)−38,113$2.38$90.71K161,922
James R. McNab
Director
Apr 28, 2017Sale(10b5-1 plan)−42,949$2.45$105.23K200,035
James R. McNab
Director
Apr 27, 2017Sale(10b5-1 plan)−37,202$2.57$95.61K242,984
James R. McNab
Director
Apr 26, 2017Sale(10b5-1 plan)−32,738$2.65$86.76K879,688
James R. McNab
Director
Apr 26, 2017Sale(10b5-1 plan)−19,814$2.65$52.51K280,186
James R. McNab
Director
Apr 25, 2017Sale(10b5-1 plan)−56,940$2.60$148.04K912,426
James R. McNab
Director
Apr 24, 2017Sale(10b5-1 plan)−42,076$2.56$107.71K969,366
James R. McNab
Director
Apr 24, 2017Sale(10b5-1 plan)−42,076$2.56$107.71K1,269,366
James R. McNab
Director
Apr 21, 2017Sale(10b5-1 plan)−45,705$2.58$117.92K1,011,442
James R. McNab
Director
Apr 21, 2017Sale(10b5-1 plan)−45,705$2.58$117.92K1,311,442
James R. McNab
Director
Apr 20, 2017Sale(10b5-1 plan)−22,541$2.66$59.96K1,057,147
James R. McNab
Director
Apr 20, 2017Sale(10b5-1 plan)−22,541$2.66$59.96K1,357,147
Reddy's Holdings Ltd Dr.
10% owner
Sep 7, 2016Buy+10,208,333$2.40$24.50M27,328,464
Martyn D. Greenacre
Director
May 27, 2016Sale−5,000$1.69$8.45K35,183
Martyn D. Greenacre
Director
May 27, 2016Option exercise+5,000$1.67$8.35K40,183
Martyn D. Greenacre
Director
May 27, 2016Option exercise+10,000$1.67$16.70K45,183
Martyn D. Greenacre
Director
May 27, 2016Sale−10,000$1.69$16.90K35,183

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
61.83%
1M shares short
Days to cover
1.1
At 1M shares a day
Change since last report
+134.3%
From 0M shares
Short volume, 20 days
53.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Curis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,962 shares on Sep 16, 2026 over the last 90 days.

See a number that looks wrong?